Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Taysha Gene Therapies, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.689 -- 00:00:05.514 Good day, everyone, and welcome to the Tayshia Gene Therapy's third quarter 2025 earnings 00:00:05.514 -- 00:00:09.738 call. At this time, all participants are in a listen-only mode. 00:00:09.738 -- 00:00:13.361 Later, you will have the opportunity to ask questions during the question and answer 00:00:13.361 -- 00:00:18.426 session. You may register to ask a question at any time by pressing the star and 1 on 00:00:18.426 -- 00:00:22.670 your telephone keypad. You may withdraw yourself from the queue by pressing star and 00:00:22.670 -- 00:00:27.094 2. Please note, this call may be recorded, and I will be standing by if you should need 00:00:27.094 -- 00:00:31.833 any assistance. It is now my pleasure to turn the conference over to Haley Collins. 00:00:31.833 -- 00:00:34.194 Please go ahead. 00:00:34.598 -- 00:00:39.826 Thank you. Good morning and welcome to our third quarter 2025 financial results and corporate 00:00:39.826 -- 00:00:44.794 update call. Earlier today, Tayshia issued a press release announcing financial results 00:00:44.794 -- 00:00:48.537 for the third quarter ended September 30th, 2025. 00:00:48.681 -- 00:00:52.847 A copy of this press release is available on the company's website and through our SEC 00:00:52.847 -- 00:00:58.522 filings. Joining me on today's call are Sean Nolan, TASHA's Chief Executive Officer, 00:00:58.522 -- 00:01:03.667 Sukumar Nagandran, President and Head of R&D, and Kamra Lam, Chief Financial 00:01:03.667 -- 00:01:09.192 Officer. We will hold a question and answer session following our prepared remarks. 00:01:09.192 -- 00:01:13.537 On today's call, we will be making forward-looking statements, including statements concerning 00:01:13.537 -- 00:01:18.822 the potential of TASHA-102, including ...